Predicted protein targets (top 4)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ALDH1A1 | P00352 | 3/20 | 0.48 |
| ▸ | HPGD | P15428 | 1/20 | 0.48 |
| ▸ | DRD3 | P35462 | 1/20 | 0.47 |
| ▸ | RPS6KA2 | Q15349 | 1/20 | 0.46 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL8183019 | 0.82 | ALDH1A1 (0.49) | ALDH1A1HPGDDRD3RPS6KA2 | |
| SCHEMBL10441170 | 0.78 | ALDH1A1 (0.50) | ALDH1A1HPGDRPS6KA2 | |
| SCHEMBL1626840 | 0.77 | CA12 (0.52) | ALDH1A1 | |
| SCHEMBL8359089 | 0.76 | ALDH1A1 (0.57) | ALDH1A1HPGDDRD3 | |
| SCHEMBL29783340 | 0.75 | ALDH1A1 (0.57) | ALDH1A1HPGD | |
| SCHEMBL20717240 | 0.75 | ALDH1A1 (0.57) | ALDH1A1HPGD | |
| SCHEMBL28466585 | 0.75 | ELANE (0.59) | — | |
| SCHEMBL92102 | 0.74 | CYP1B1 (0.67) | ALDH1A1HPGDDRD3 | |
| SCHEMBL29969387 | 0.74 | CYP1B1 (0.67) | ALDH1A1HPGDDRD3 | |
| SCHEMBL3779983 | 0.74 | CA12 (0.46) | ALDH1A1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-8207169-B2 | Substituted [1,2,4]triazolo[4′,3′:1,6]pyrido[2,3-b]pyrazines of the formula D | MSD K.K. (JP) | 2012-06-26 | — | — | US | disclosed |
| US-20110092511-A1 | INHIBITORS OF AKT ACTIVITY | MERCK SHARP & DOHME LLC | 2011-04-21 | — | — | US | disclosed |
| WO-2009148916-A1 | INHIBITORS OF AKT ACTIVITY | MERCK & CO., INC. (US) | 2009-12-10 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20110092511-A1 | INHIBITORS OF AKT ACTIVITY | AKT1S1, AKT1, PIK3CA | ALDH1A1 4132/4885HPGD 3866/4885DRD3 4224/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.